CoChat

Role of P‐glycoprotein‐mediated secretion in absorptive drug permeabiity: An approach using passive membrane permeability and affinity to P‐glycoprotein††Dedicated to Prof. B. C. Lippold on the occasion of his 60th birthday.

Doppenschmitt, Stephan, Spahn‐Langguth, Hildegard, Regårdh, Carl Gunnar, Langguth, Peter · 1999 · Journal of Pharmaceutical Sciences
Cited by 127

The DOI matches its Crossref record.

Abstract

It has been shown in vivo and in vitro that P-glycoprotein (P-gp) may be able to influence the permeability of its substrates across biological membranes. However, the quantitative contribution of the secretion process mediated by P-gp on the overall permeability of membranes has not been determined yet. In particular, observations need to be clarified in which substrates showing high affinity to P-glycoprotein, e.g., verapamil, apparently do not seem to be greatly influenced by P-gp in their permeability and consequently also with respect to their extent of GI-absorption after oral administration, whereas weaker substrates of P-gp, e.g., talinolol, have clearly shown P-gp-related absorption phenomena such as nonlinear intestinal permeability and bioavailability. Experiments with Caco-2 cell monolayers and mathematical simulations based on a mechanistic permeation model should aid in clarifying the underlying mechanism for these observations and quantifying the influence of passive membrane permeability and affinity to P-gp to the overall transmembrane drug flux. In addition, the concentration range of drug at which P-glycoprotein-mediated transport across the biological membrane is relevant should be examined. The permeability of various drugs in Caco-2 monolayers was determined experimentally and modeled using a combination of passive absorptive membrane permeability and a Michaelis-Menten-type transport process in the secretory direction. The passive permeabilities were experimentally obtained for the apical and basolateral membrane by efflux experiments using Caco-2 monolayers in the presence of a P-gp inhibitor. The Michaelis-Menten parameters were determined by a newly developed radioligand-binding assay for the quantification of drug affinity to P-gp. The model was able to accurately simulate the permeability of P-glycoprotein substrates, with differing passive membrane permeabilities and P-glycoprotein affinities. Using the outlined approach, permeability vs donor-concentration profiles were calculated, and the relative contribution of passive and active transport processes to the overall membrane permeability was evaluated. A model is presented to quantitatively describe and predict direction-dependent drug fluxes in Caco-2 monolayers by knowing the affinity of a compound to the exsorptive transporter P-gp and its passive membrane permeability. It was shown that a combination of high P-gp affinity with good passive membrane permeability, e.g., in the case of verapamil, will readily compensate for the P-gp-mediated reduction of intestinal permeability, resulting in a narrow range in which the permeability depends on the apical drug concentration. On the other hand, the permeability of compounds with low passive membrane permeability (e. g., talinolol) might be affected over a wide concentration range despite low affinity to P-gp.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/js980378j

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 15

  1. Spahn‐Langguth, 1998, P‐Glycoprotein transporters and the gastrointestinal tract: Evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound, Int. J. Clin. Pharmacol. Ther., 36, 16
  2. Greenberger, 1994, ATP‐Binding Cassette Proteins, Common Denominators between Ion Channels, Transporters, and Enzymes, Trends Cardiovasc. Med., 4, 193, 10.1016/1050-1738(94)90057-4 · DOI
  3. Müller, 1997, Molecular aspects of hepatobiliary transport, Am. J. Physiol., 272, G1285
  4. Smit, 1993, Homologous disruption of the murine mdr2 P‐glycoprotein gene leads to a complete absence of phospholipid in the bile and liver desease, Cell, 75, 451, 10.1016/0092-8674(93)90380-9 · DOI · Paper page
  5. Wacher, 1995, Overlapping substrate specificities and tissues distribution of cytochrome P‐450 3A and P‐glycoprotein have implications for drug delivery and activity in cancer chemotherapy, Mol. Carcinogen., 13, 129, 10.1002/mc.2940130302 · DOI · Paper page
  6. Döppenschmitt, 1999, Characterization of Binding Properties to Human P‐glycoprotein: Development of a 3‐H‐Verapamil Radioligand‐Binding Assay, J. Pharmacol. Exp. Ther., 288, 348
  7. Döppenschmitt, 1998, Radioligand‐Binding Assay Employing P‐Glycoprotein‐Overexpressing Cells: Testing Drug Affinities to the Secretory Intestinal Multidrug Transporter, Pharm. Res., 15, 1001, 10.1023/A:1011965707998 · DOI
  8. Ayesh, 1996, Cooperative, competitive and noncompetitive interactions between modulators of P‐glycoprotein, Biochim. Biophys. Acta, 1316, 8, 10.1016/0925-4439(96)00008-7 · doi:10.1016/0925-4439(96)00008-7
  9. Shah, 1992, Bioanalytical method validation, J. Pharm. Sci., 81, 309, 10.1002/jps.2600810324 · DOI · Paper page
  10. Stein, 1997, Kinetics of the multidrug transporter (P‐glycoprotein) and its reversal, Physiol. Rev., 77, 545, 10.1152/physrev.1997.77.2.545 · DOI · Paper page
  11. Kim, 1997, Experimentally induced changes in the endocytic traffic of P‐glycoprotein alter drug resistance of cancer cells, Am. J. Physiol., 63, C687, 10.1152/ajpcell.1997.273.2.C687 · DOI
  12. Wetterich, 1996, Evidence for Intestinal Secretion as an Additional Clearance Pathway of Talinolol Enanti‐omers: Concentration‐ and Dose‐dependent Absorption in Vitro and in Vivo, Pharm. Res., 13, 514, 10.1023/A:1016029601311 · DOI
  13. Eichelbaum, 1984, Clinical Pharmacology of Calcium Antagonists: A Critical Review, J. Cardiovasc. Pharmacol., 6, S963
  14. Hoffmann, 1995, Method to estimate the rate and extent of intestinal absorption in conscious rats using an absorption probe and portal blood sampling, Pharm. Res., 12, 889, 10.1023/A:1016221322886 · doi:10.1023/a:1016221322886
  15. Hunter, 1997, Intestinal secretion of drugs. The role of P‐glycoprotein and related drug efflux systems in limiting oral drug absorption, Adv. Drug Deliv. Rev., 25, 129, 10.1016/S0169-409X(97)00497-3 · DOI · Paper page

Cited by

See all 127

Metadata

Authors
Doppenschmitt, S., Spahn‐Langguth, H., Regårdh, C. G., & Langguth, P.
Venue
Journal of Pharmaceutical Sciences
Published
1999-10
Volume
88
Issue
10
Pages
1067-1072
ISSN
0022-3549 (ISSN-L)
OpenAlex
W1980418252
Cited by
127
References
0
FWCI
2.32
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Role of P‐glycoprotein‐mediated secretion in absorptive drug permeabiity: An approach using passive membrane permeability and affinity to P‐glycoprotein††Dedicated to Prof. B. C. Lippold on the occasion of his 60th birthday. https://app.cochat.ai/papers/10.1021/js980378j
The paper
Doppenschmitt, S., Spahn‐Langguth, H., Regårdh, C. G., & Langguth, P. (1999). Role of P‐glycoprotein‐mediated secretion in absorptive drug permeabiity: An approach using passive membrane permeability and affinity to P‐glycoprotein††Dedicated to Prof. B. C. Lippold on the occasion of his 60th birthday. Journal of Pharmaceutical Sciences. https://doi.org/10.1021/js980378j

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.